Psychopharmacology of borderline personality disorder

Current Psychiatry Reports

Volumn 6, Issue 3, 2004, Pages 225-231

  Raj, Y Pritham ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLONAZEPAM; DOCOSAHEXAENOIC ACID; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; HALOPERIDOL; IBUPROFEN; ICOSAPENTAENOIC ACID ETHYL ESTER; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PHENELZINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TIOTIXENE; TRANYLCYPROMINE; TRIFLUOPERAZINE; VALPROATE SEMISODIUM; VENLAFAXINE;

BODY WEIGHT DISORDER; BORDERLINE STATE; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; DRUG RESEARCH; DRUG USE; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; HUMAN; LOW DRUG DOSE; PSYCHOPHARMACOLOGY; REVIEW;

EID: 3142764603     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-004-0068-y     Document Type: Review

References (34)

1. Gunderson JG, Kolb JE: Discriminating features of borderline patients. Am J Psychiatry 1978, 135:792-796.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 4-TR. Washington, DC: American Psychiatric Press, Inc; 2000.
3. Swartz M, Blazer D, George L, Winfield I: Estimating the prevalence of borderline personality disorder in the community. J Personal Disord 1990, 4:257-272.
4. Clarkin JF, Widiger TA, Frances A, et al.: Prototypic typology and the borderline personality disorder. J Abnorm Psychol 1983, 92:263-275.
5. McGlashan TH: The Chestnut Lodge follow-up study, III: long-term outcome of borderline personalities. Arch Gen Psychiatry 1986, 43:20-30.
6. Comtois KA, Russo J, Snowden M, et al.: Factors associated with high use of public mental health services by persons with borderline personality disorder. Psychiatr Serv 2003, 54:1149-1154.
7. Hengeveld MW, Rooymans HG, Vecht-van den Bergh R: Psychiatric consultation in a Dutch university hospital: a report on 1814 referrals, compared with a literature review. Gen Hosp Psychiatry 1984, 6:271-279.
8. Lahmeyer HW, Reynolds CF, III, Kupfer DJ, King R: Biological markers in borderline personality disorder: a review. J Clin Psychiatry 1989, 50:217-225.
9. Levitt AJ, Joffe AT, Ennis J, et al.: The prevalence of cyclothymia in borderline personality disorder. J Clin Psychiatry 1990, 51:335-339.
10. Deltito J, Maritn L, Riefkohl J, et al.: Do patients with borderline personality disorder belong to the bipolar spectrum? J Affect Disord 2001, 67:221-228.
11. Linehan MM, Kanter JW, Comtois KA: Dialectical behavior therapy for borderline personality disorder: efficacy; specificity, and cost-effectiveness. In Psychotherapy. Indications and Outcomes. Washington, DC: American Psychiatric Press; 1999.
12. Verheul R, Van Den Bosch LM, Koeter MW, et al.: Dialectical behavior therapy for women with borderline personality disorder: 12-month, randomized clinical trial in The Netherlands. Br J Psychiatry 2003, 182:135-140.
13. Rizvi SL, Linehan MM: Dialectical behavior therapy for personality disorders. Curr Psychiatry Rep 2001, 3:64-69.
14. Gunderson JG: Borderline Personality Disorder: A Clinical Guide. Washington, DC: American Psychiatric Press; 2001.
15. DeBattista C, Mueller K: Is electroconvulsive therapy effective for the depressed patient with comorbid borderline personality disorder? J ECT 2001, 17:91-98.
16. Practice guideline for the treatment of patients with borderline personality disorder. http://www.psych.org/psych_pract/treatg/pg/ borderline_revisebook_index.cfm. Accessed Feb 12, 2004.
17. Sanderson C, Swenson C, Bohus M: A critique of the American Psychiatric Practice Guideline for the Treatment of Patients with Borderline Personality Disorder. J Personal Disord 2002, 162:122-129.
18. Goldberg SC, Schulz SC, Schulz PM, et al.: Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986, 43:680-686.
19. Soloff PH, George A, Nathan RS, et al.: Progress in pharmacotherapy of borderline disorders: a double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 1986, 43:691-697.
20. Cowdry RW, Gardner DL: Pharmacotherapy of borderline personality disorder. Arch Gen Psychiatry 1988, 45:111-119.
21. Frankenburg FR, Zanarini MC: Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002, 63:442-446.
22. De la Fuente JM: A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 1994, 4:479-486.
23. Zanarini MC, Frankenburg FR: Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 2003, 160:167-169.
24. Mickleborough TD, Murray RL, Ionescu AA, Lindley MR: Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes. Am J Respir Crit Care Med 2003, 168:1181-1189.
25. Thies F, Garry JM, Yaqoob P, et al.: Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomized controlled trial. Lancet 2003, 361:477-485.
26. Zanarini MC, Frankenburg FR: Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001, 62:849-854
27. Frankenburg FR, Zanarini MC: Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993, 34:402-405.
28. Salzman C, Wolfson AN, Schatzberg A, et al.: Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacology 1995, 15:23-29.
29. Rinne T, van den Brink W, Wouters L, van Dyck R: SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002, 159:2048-2054.
30. Hollander E, Allen A, Lopez RP, et al.: A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001, 62:199-203.
31. Soloff PH, Cornelius J, Anselm G, et al.: Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993, 50:377-385.
32. Cornelius JR, Soloff PH, Perel JM, Ulrich RF: Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry 1993, 150:1843-1848.
33. Zanarini MC, Frankenburg FR, Khera GS, Bleichmar J: Treatment histories of borderline inpatients. Compr Psychiatry 2001, 42:144-150.
34. The McLean Center for the Treatment of Borderline Personality Disorder. http://www.mcleanhospital.org/Adult/borderline.html. Accessed February 12, 2004.